Biotech and Pharmaceuticals Biotechnology

More

  • Clovis Oncology CEO: We do not cause diabetes

    A new Clovis cancer drug has been associated with high blood sugar and linked to diabetes in trial. CEO Patrick J. Mahaffy, Clovis Oncology, weighs in on the recent report.

  • Clovis Oncology CEO: Competing with AZN

    Clovis Oncology CEO Patrick J. Mahaffy, talks about competing with larger companies like AstraZeneca when it comes to new cancer drugs. You compete on data, he says.

  • Pazdur: Breakthrough cancer treatments

    CNBC biotech & pharma reporter Meg Tirrell talks to Richard Pazdur, the FDA's cancer czar about how far we've come in cancer treatment, breakthrough designations and if chemotherapy will soon be a thing of the past.

  • ASCO cancer care conference kicks off

    In the U.S., half of all men and a third of all women will develop cancer in their lifetimes. CNBC's Meg Tirrell reports which stocks analysts are eyeing into the conference.

  • War on cancer

    The big topic at this year's cancer care conference ASCO will be immunotherapy drugs. CNBC's Meg Tirrell explains how these drugs work.

  • Valeant raises Allergan bid

    Valeant is upping its offer for Allergan in a proposal that could now be worth more than $50 billion, reports CNBC's Meg Tirrell.

  • Why Mesoblast is big on the stem-cell therapy space

    Silviu Itescu, CEO of Mesoblast, highlights sources of growth that may propel stem-cell therapy into a multi billion-dollar market by 2020.

  • How not to fear biotech

    Discussing hot picks in the biotech space, with Matthew Roden, UBS executive director.

  • Big gains for Nasdaq

    CNBC's Seema Mody reveals what stocks and sectors are driving the Nasdaq rally today.

  • Tax rate puts US at competitive disadvantage: Merck CEO

    CNBC's Meg Tirrell speaks to Ken Frazier, Merck chaiman & CEO, about selling the company's consumer unit to Bayer. Frazier also gives his stance on mega-mergers and U.S corporate tax rate.

  • End-game of polio 'fragile': Expert

    Dr. William Schaffner of the Vanderbilt School of Medicine, addresses the latest polio outbreaks, and the importance of vaccinating children.

  • 'Super bug' spreads

    CNBC's Meg Tirrell reports the World Health Organization has confirmed about 262 cases of the MERS virus, of which 93 people have died. Dr. William Schaffner of the Vanderbilt School of Medicine, provides insight.

  • Apple CEO Tim Cook looks on at an Apple Store on September 20, 2013 in Palo Alto, California.

    Apple is expanding to medical technology. The company is recruiting a team of medical executives and has offered hints of the iWatch and others.

  • AstraZeneca rejects new Pfizer bid

    AstraZeneca has rejected Pfizer's sweetened bid claiming it undervalues the company. The "Squawk on the Street" news team shares their thoughts on the latest bid and the U.S. tax code.

  • Cramer: Pfizer solution loved by market

    The "Squawk on the Street" news team break down Merck's quarterly earnings beat and discuss the state of big pharma and taxes.

  • Pfizer, AstraZeneca about drug pipeline: Pro

    Discussing Pfizer's push for a $100 billion deal for AstraZeneca, with Seamus Fernandez Leerink Partners managing director.

  • Pfizer pushes for $100 billion AstraZeneca deal

    Pfizer is working on its next move in a potential $100 billion battle for AstraZeneca after having two bids rejected. CNBC's Meg Tirrell reports buying AstraZeneca would boost Pfizer's cancer drug pipeline.

  • Analyst suggests Allergan buy Shire

    CNBC's Meg Tirrell reports a Cowen analyst is suggesting Allergan buy ADHD drug maker Shire. The FMHR traders, provide perspective.

  • Biogen barreling down on Alzheimer's

    CNBC's Meg Tirrell speaks with George Scangos, Biogen Idec CEO, about the drug maker's fight against MS and Alzheimer's. Scangos also comments on Valeant's bid for Alllergan.

  • Tech & biotech plays for your portfolio

    Kevin Caron, Stifel Private Client Group market strategist, and Doug MacKay, Broadleaf Partners president & CIO, discuss signs of a tech bubble and share their investment strategies on hot technology stocks.